Qi Bian

Qi Bian

Auto-generated profile, based on publicly available information

Qi Bian

Nephrology Department, The PLA Naval Medical University, Shanghai Changhai Hospital, Shanghai, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2016 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
DMDita Maixnerova
Dita Maixnerova
CRColin Reily
Colin Reily
QBQi Bian
Qi Bian
MNMichaela Neprasova
Michaela Neprasova
JNJan Novak
Jan Novak
Vladimir TesarVladimir Tesar
Vladimir Tesar
We have summarized the latest findings on markers for progression of immunoglobulin A (IgA) nephropathy (IgAN), the most common primary glomerulonephritis with a high prevalence among end-stage renal disease (ESRD) patients. The clinical predictors of renal outcome in IgAN nephropathy, such as proteinuria, hypertension, and decreased estimated glomerular filtration rate (eGFR) at the time of the diagnosis, are well known. The Oxford classification of IgAN identified four types of histological lesions (known as the MEST score) associated with the development of ESRD and/or a 50 % reduction in eGFR. In addition, the role of genetic risk factors associated with IgAN is being elucidated by genome-wide association studies, with multiple risk alleles described. Recently, biomarkers in serum (galactose-deficient IgA1, IgA/IgG autoantibodies against galactose-deficient IgA1, and soluble CD 89-IgA complexes) and urine (soluble transferrin receptor, interleukin-6/epidermal growth factor ratio, fractalkine, laminin G-like 3 peptide, κ light chains, and mannan-binding lectin) have been identified. Some of these biomarkers may represent candidates for the development of noninvasive diagnostic tests, that would be useful for detection of subclinical disease activity, monitoring disease progression, assessment of treatment, and at the same time circumventing the complications associated with renal biopsies. These advances, along with future disease-specific therapy, will be helpful in improving the treatment effectiveness, prognosis, and the quality of life in connection with IgAN.

5 October 2015 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
BSBin Song
Bin Song
QBQi Bian
Qi Bian
YZYi-Jie Zhang
Yi-Jie Zhang
CSCheng-Hao Shao
Cheng-Hao Shao
GLGang Li
Gang Li
XHXian-Gui Hu
Xian-Gui Hu
Apoptosis-stimulating of p53 protein 2 (ASPP2) is one of the ASPP family members and it has been reported to be associated with human cancer. However, the role of it in pancreatic cancer is still not clear. We analyzed the expression level of ASPP2 in cancer tissue samples with RT-qPCR, Western Blotting assay and immunohistochemistry staining. We studied the biological function of ASPP2 and its mechanism with gene overexpression and gene silencing technologies. We determined the sensitivity of pancreatic cells with differential ASPP2 level to gemcitabine and whether autophagy inhibition affected the gemcitabine resistance, both in vitro and in vivo. Expression of ASPP2 was downregulated in cancerous tissues in comparison with para-cancerous tissues. ASPP2 expression was linked to clinical outcomes in patients and down-regulation of ASPP2 increased cell proliferation, autophagic flux, the activity of AMP Kinase of pancreatic cancer cells and vice versa. Knockdown of ASPP2 results in increased resistance to gemcitabine, which was attributed to the enhanced autophagy. ASSP2 expression is lower in cancerous tissues and decreased ASPP2 lead to higher cancer cells proliferation and autophagic flux, which contribute to the gemcitabine resistance.

17 August 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
WRWeifu Ren
Weifu Ren
QBQi Bian
Qi Bian
YCYan Cai
Yan Cai
Kidney disease is a global health concern with an enormous expense. It is estimated that more than 10% of the population worldwide is affected by kidney disease and millions of patients would progress to death prematurely and unnecessarily. Although creatinine detection and renal biopsy are well-established tools for kidney disease diagnosis, they are limited by several inevitable defects. Therefore, diagnostic tools need to be upgraded, especially for the early stage of the disease and possible progression. As one of the most common post-translational modifications of proteins, N-glycosylation plays a vital role in renal structure and function. Deepening research on N-glycosylation in kidney disease provides new insights into the pathophysiology and paves the way for clinical application. In this study, we reviewed recent N-glycosylation studies on several kidney diseases. We also summarized the development of mass spectrometric methods in the field of N-glycoproteomics and N-glycomics.

21 March 2024 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
WRWeifu Ren
Weifu Ren
JSJing Sun
Jing Sun
LZLingyan Zhang
Lingyan Zhang
WHWei He
Wei He
ZGZhiyong Guo
Zhiyong Guo
QBQi Bian
Qi Bian
Background Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy accounts for the majority of membranous nephropathy; however, few studies have determined the prognostic impact and clinical application of renal pathologic change on this disease. Methods A retrospective cohort study of 262 patients with PLA2R-associated membranous nephropathy was conducted. The total renal chronicity score calculated according to the degree of glomerulosclerosis, interstitial fibrosis, tubular atrophy, and arteriosclerosis was applied to evaluate renal chronicity. Baseline bias was adjusted by inverse probability weight when assessing the prognostic impact of chronicity, and multiple parameters were used to evaluate the application value of renal chronicity. Results During a median follow-up of 24.5 months, renal outcome (kidney function deterioration and/or end-stage kidney disease) was observed in 22 (8.40%) patients. Not only did a higher total renal chronicity score independently predict renal outcome [odds ratio (OR): 1.562, 95% confidence interval (CI) 1.073–2.273, P = 0.020], but non-minimal chronicity was also an independent risk factor for renal outcome (OR: 3.170, 95% CI 1.040–9.659, P = 0.042). Moreover, the membranous nephropathy risk classification in the Kidney Disease: Improving Global Outcomes (KDIGO) guideline integrated with non-minimal chronicity showed improvements in categorical net reclassification (0.174, 95% CI 0.012–0.335, P = 0.035), continuous net reclassification (0.462, 95% CI 0.087–0.838, P = 0.016), and integrated discrimination (0.019, 95% CI 0.003–0.035, P = 0.020) compared to the original classification. Conclusions Renal chronicity is closely associated with renal outcomes in PLA2R-associated membranous nephropathy, and combining the KDIGO risk classification with chronicity scores may provide a more accurate prognostic prediction. Graphical abstract

9 September 2023 in The American Journal of Surgery
Verified
Journal Article
Closed access
SLSiqian Li
Siqian Li
WRWeifu Ren
Weifu Ren
XYXiaofei Ye
Xiaofei Ye
LZLinyan Zhang
Linyan Zhang
BSBin Song
Bin Song
QBQi Bian
Qi Bian

7 July 2022 in Analytica Chimica Acta
Verified
Journal Article
Closed access
YCYan Cai
Yan Cai
WRWeifu Ren
Weifu Ren
HWHaiyan Wang
Haiyan Wang
QBQi Bian
Qi Bian